INTRODUCTION
Gene expression profiling using whole genome microarrays has generated large amounts of data in various clinical contexts. One goal of these studies is the discovery of clinically relevant patient subgroups, e.g. groups of patients requiring a particular treatment.
An example from lymphoma research Alizadeh et al., 2000 define two new subtypes of diffuse large B-cell lymphoma based on a hierarchical clustering analysis using a functionally restricted set of genes. The two disease entities refer to distinct differentiation stages of B-cells. Monti et al., 2005 postulate a different partitioning of diffuse large B-cell lymphomas supported by genes which have been excluded from the first analysis. Their disease entities reflect proliferation properties of the B-cell malignancies. None of the results can be easily proven wrong. In fact, they do not contradict each other. The two research groups had a priori different notions as to which genes are relevant. This led to two dissimilar but relevant clusterings of samples.
Different genes -different distances -different results In the context of class discovery, we cluster patient profiles. For clustering, pairwise distances between these objects are calculated. A decision to use the Euclidean or any other metric to do this, does not yet uniquely define these distances, though. Which genes to include in the analysis is very important. Using all measured genes as such is not a good choice. Several independent molecular characteristics of the patients like age, gender, and disease status will overlap and obscure the result. Gene selection is called for but certainly affects the clustering. Each choice of a gene set to use defines a particular distance between any two samples. Different gene sets lead to different distances between the same objects, although we always use the Euclidean metric to compute them. In many clinical studies, gene selection is used for unsupervised analysis either in order to reduce noise in the expression data (e.g., Cario et al., 2005) or, in addition, to focus on reproducible features (e.g., Bhattacharjee et al., 2001; Monti et al., 2005) . However, little attention on the effect of gene discarding on the resulting disease class definition has been given.
The concept of our algorithm Instead of selecting genes according to purely statistical characteristics, we suggest a systematic gene selection approach according to functional annotation. We describe an algorithm that generates a list of alternative clusterings using different gene sets to compute distances between samples. We derive candidate gene sets from functional annotation data, and filter the list by a novel significance measure for clustering strength.
Previous work Clustering of gene expression data is routine in bioinformatics. Several methods have been suggested in this field (for a review, see Chapter 4 of Speed, 2003) . Various approaches to score the quality of clusterings, and to determine the best number of clusters exist (Dudoit & Fridlyand, 2002; Kerr & Churchill, 2001) . All these methods have in common that the underlying metrics need to be specified beforehand. Several authors also have suggested ways to judge stability and statistical significance of clusters (Halkidi et al., 2001; Lange et al., 2004; McShane et al., 2002; Monti et al., 2003; Munneke et al., 2005) . Semi-supervised clustering approaches include additional clinical information about patients. Bullinger et al., 2004 as well as suggest finding classes of patients using a clustering metric derived from the expression data and additional survival times. In a completely unsupervised setting, biclustering (Cheng & Church, 2000; Tanay et al., 2004; Madeira & Oliveira, 2004) and class-finding algorithms (von Heydebreck et al., 2001; Varma & Simon, 2004) combine the gene selection process with the clustering. These methods produce alternative clusterings and characterize them by underlying gene sets. Unfortunately, such methods are rarely used in clinical studies. One reason might be that a large set of alternative clusterings is hard to interpret, unless the driving genes have a clear functional focus.
The role of functional annotations A major shortcoming of class discovery algorithms is that they treat gene expression levels as anonymous variables. For many genes, however, a lot is known about their function and their role in cellular processes. Such knowledge is stored in databases like the Gene Ontology (Ashburner et al., 2000) , Transpath (Schacherer et al., 2001) , Biocarta (http://www.biocarta.com) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa, 1996) . Today, such annotations are routinely used to interpret results produced by statistical analysis. Tools for such a-posteriori analysis include Beissbarth & Speed, 2004; Dennis et al., 2003; Adryan & Schuh, 2004; Doniger et al., 2003; Subramanian et al., 2005; Grossmann et al., 2006 .
A-priori use of functional annotations Unlike a-posteriori methods, we propose using annotations within the statistical analysis of the expression data. In different contexts this a-priori use of functional annotations has already been investigated. Pavlidis et al., 2002 and Zien et al., 2000 use functional annotations to improve the sensitivity of algorithms for detecting differentially expressed genes. Rahnenführer et al., 2004 apply pathway annotations to investigate metabolic pathways. Subclass finding in complex clinical phenotypes using functional annotations is the topic of . Here, we apply similar concepts to the problem of molecular class discovery in patients.
Outline of the paper In the next section, we describe the clustering procedure as well as the scoring of clustering results. In Section 3, we illustrate the usefulness of functional gene annotation for producing alternative clusterings of samples on a number of cancer related clinical microarray datasets. Finally, we discuss possible extensions of the method and interpret our observations from a biological perspective in Section 4.
METHODS
The key idea for our class discovery algorithm is to use meaningful gene sets for computing distances between samples. For practical use, it is desirable to have functional rationales characterizing clusterings, such as clusterings related to proliferation or apoptosis. To this end, we define candidate gene sets using functional annotations, and call the resulting clusterings annotation driven.
We use the k-means algorithm to generate clusterings based on candidate gene sets. The quality of these clusterings is assessed using the diagonal linear discriminant (DLD) score (von Heydebreck et al., 2001) . In order to determine the statistical significance of scores, we also compute DLD scores for clusterings driven by randomly chosen gene sets. Empirical p-values are calculated and false discovery rates (FDR) computed according to Benjamini and Hochberg (Benjamini & Hochberg, 1995) . Finally, we filter the list of clusterings for minimal subgroup size and to control the FDR. In a nutshell, the algorithm consists of the following steps:
For each biological term / pathway of interest, denoted B i :
1. Find all n B i genes annotated to B i and discard all others.
2. Perform 2-means clustering on the reduced expression matrix. This yields an annotation-driven clustering C B i .
3. Compute DLD score S(C B i ) for this clustering.
4. Draw 10000 random gene sets of size n B i from the set of all measured genes. For each of them compute steps 2 and 3. This yields a vector rn B i of 10000 scores.
5. Assign an empirical p-value to the original clustering, denoting the proportion of entries of rn B i being greater or equal than S(C B i ).
In the following, we provide more details on certain steps of the procedure.
Annotation data
We suggest the use of annotation data to generate candidate gene sets. Genes in a candidate set have common involvement in biological processes or pathways. To generate such gene sets, pathway databases such as KEGG and Gene Ontology are particularly adequate. Sets of genes collected for a particular application from literature or a biologist's experience are possible alternatives. Very small gene sets should not be considered, since clusterings supported by very few genes are unlikely to represent a clustering of biological interest. On the other hand, sets containing too many genes are prone to be very unspecific, and thus their results are of little explanatory power.
Distance metric
K-means clustering is based on pairwise object dissimilarities. Objects in our case are patient expression profiles. We obtain dissimilarity measures from the family of restricted Euclidean metrics, which we define next. Let (x i , x i ) be any two expression profiles, both containing measured expression values for p genes. Reducing the expression profiles to a limited set of genes before computing the distance, is the same as computing a Euclidean distance specific for gene set G between the original profiles
where I j∈G is an indicator variable taking the value 1 if gene j is in set G and 0 otherwise. We call D G a restricted Euclidean metric on patient space.
By selecting different gene sets before clustering, we choose different measures of distance between any two expression profiles. Since the choice of the distance measure affects the outcome of clustering stronger than the choice of the clustering algorithm (see Hastie et al., 2001, chap. 14) , clusterings of the same samples with different metrics disagree substantially.
K-means initialization
K-means clustering critically depends on its initialization step. We derive an initialization based on the first split of a divisive hierarchical clustering (Kaufman & Rousseeuw, 1990, chap. 6) . Of the resulting two clusters, we compute centroids which provide the starting points for the k-means algorithm (MacQueen, 1967) . This has been shown to outperform standard k-means with random starting points (Milligan & Sokol, 1980) . In other words, k-means is used to refine individual clusters and to correct inappropriate assignments made by the hierarchical method.
Scoring clusterings
For clustering evaluation, we employ the diagonal linear discriminant (DLD) score, adopted from von Heydebreck et al., 2001: Let X be the reduced expression matrix with rows containing the genes from the set of interest and columns representing the patient samples. Given a clustering C of samples, i.e. a binary vector of class labels for classes A and B, we are interested in genes, which best reflect this class division in their expression. A natural score for this purpose is Student's t-statistic. We only keep those 50 genes with the highest absolute t-statistic. All genes are kept for functional groups with fewer than 50 genes. Disease entities typically constitute expression changes of many genes. This is why we avoid clusterings with very few supporting genes by discarding the genes with the largest absolute t-statistic. The number of genes discarded is a user-defined parameter of our method, which defaults to 5. Discarding the respective rows (genes) from X, yields a shortened expression matrix X * . Now, we project the samples (columns) of X * onto a one-dimensional space using the projection method from the classification step of diagonal linear discriminant analysis (Mardia et al., 1979) . The DLD-Score S of a clustering C is the Student's t-statistic of the two clusters of C on this projection.
Assessing clustering significance
We introduce a new approach to address the question whether an annotationdriven clustering is statistically significant. To this aim, we observe clusterings based on randomly drawn gene sets, which have the same size as the set of functionally related genes but otherwise no restrictions on included genes. For each of these random gene sets, we find the optimal clustering and compute its DLD-Score as described above. The score derived from the annotation-driven clustering is compared with these random scores.
The DLD-Scores derived from random gene sets define a null-distribution of scores for gene sets of the given size. For each annotation-driven clustering C, we can compute an empirical p-value π E (C) denoting the proportion of random scores being equal to or greater than the annotationdriven clustering's DLD-score.This empirical p-value provides us with a measure of significance for clusterings.
Multiple testing
The algorithm described so far, determines an empirical p-value for each term we can find associated genes for. Depending on the employed annotation sources and the microarray at hand, hundreds of terms are considered to generate annotation-driven clusterings. Hence, the determination of empirical p-values is subject to multiple testing. A conservative approach to correct for the multiple testing problem is to determine false discovery rates according to Benjamini & Hochberg, 1995. We employ this correction although its results are to be interpreted with care given the many dependencies between GO and KEGG terms which share commonly associated genes. First attempts to decorrelate overlapping gene sets for the gene set enrichment problem are described in Alexa et al., 2006; Grossmann et al., 2006 but difficult to transfer to our method.
Implementation
We have implemented annotation-based clustering in the statistical programming language R (Ihaka & Gentleman, 1996; R Development Core Team, 2005) . We employ the divisive hierarchical clustering method from the cluster package and the implementation of k-means clustering (Hartigan & Wong, 1979 ) from R's stats package. The implementation of the DLD score is taken from the isis package (von Heydebreck et al., 2001) . We retrieve gene annotations for GO and KEGG from meta-data packages of the Bioconductor project (Gentleman et al., 2004) . Our code is available in the R package adSplit from http://compdiag.molgen.mpg.de/software. The package is also part of Bioconductor release 1.9.
RESULTS
We show results of our method on several cancer related datasets from clinical gene expression studies. We focus on the use of Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) for annotations.
Expression data
We investigate the behavior of our clustering procedure on 15 clinical microarray studies. These studies are concerned with diagnostic and prognostic issues in the context of brain tumors (Freije et al., 2004; Nutt et al., 2003; Pomeroy et al., 2002; Rickman et al., 2001) , breast cancer (Huang et al., 2003; West et al., 2001) , leukemia (Armstrong et al., 2002; Cheok et al., 2003; Ross et al., 2004; Willenbrock et al., 2004; Yeoh et al., 2002) , lung cancer (Beer et al., 2002; Bhattacharjee et al., 2001 ) and prostate tumors (Singh et al., 2002) . All 15 microarray studies are based on Affymetrix GeneChip R technology. Eight datasets are generated using the genome wide HG-U95Av2 microarray based on release 95 of UniGene (Schuler, 1997) , four studies are based on the older HU6800 chip, in two studies the newer HG-U133A chip based on release 133 of UniGene was applied, and one team worked with the HGFocus chip, a microarray holding a subset of the probe-sets of the HG-U133A chip. Table 1 holds further information on the results obtained for these 15 studies. For each of these datasets, gene expression profiles were background corrected and normalized on probe level using variance stabilization (Huber et al., 2002) before summarizing the probes into probe-set expression levels using median polish (Tukey, 1977) as suggested in RMA (Irizarry et al., 2003) . The preprocessing steps are crucial to the clustering method. The variance stabilization method accounts for labeling effects and hybridization efficiency. Therefore, it improves gene to gene comparability of expression values but avoids blowing up the variance of low-variance genes, as genewise standardization would do. The summarization method using median polish further reduces adverse effects of probewise hybridization affinity. We used implementations of the cited preprocessing methods from Bioconductor (Gentleman et al., 2004) .
Annotation data
For the systematic exploration of functional gene annotations, we suggest the use of the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). GO holds 17,601 biological terms, while KEGG comprises 231 pathways. For the considered Affymetrix microarrays, Table 2 states the number of terms and pathways, which have more than 20 probe-sets but less than 10% of all probe-sets on the chip annotated.
Strikingly many GO terms have very few genes attributed: more than 75% of all terms hold less than 20 probe-sets. On the other hand, very few terms are too general holding more than 10% of the genes on the microarrays. KEGG also defines some very small gene sets, but roughly two thirds hold more than 20 genes. The cellular function of many genes is still unknown. Hence for those genes no functional annotations are available. At present we can only discard these genes, thus loosing information. This loss will become less important as functional knowledge increases. On commercial Affymetrix oligonucleotide microarrays, many genes are represented by more than one probe-set, thus several rows in an expression matrix give measurements for the same gene. When extracting probe-sets with a common annotation, either all or none of the probe-sets representing the same gene are included. When drawing random sets of probe-sets, we mimic this fact, by actually drawing Entrezgene-IDs and including all probe-sets mapped to these in our random set. In this manner, we make sure that random scores actually correspond to random gene sets rather than random sets of probe-sets.
Annotation driven clusterings
We observe that many annotation driven clusterings of patients obtain low empirical p-values. As illustrated in Figure 1 for the leukemia study by Yeoh et al. (Yeoh et al., 2002) , the distribution of empirical p-values has a peak close to zero. Apparently, certain gene sets with common functional annotation provide a better basis for clustering samples than random sets of genes. Moreover, the clusterings corresponding to low p-values are of particular interest for the biological focus of their supporting genes.
Our second observation is that many clusterings with small pvalues assign only few samples to one of the two clusters. In addition to a stringent p-value, we therefore also require a minimum group size of at least five samples for interesting clusterings. For the datasets analyzed, we thus obtain the number of interesting clusterings shown in the column ' C' of Table 1 .
From the same table, we see that our clustering procedure behaves differently on different datasets. While it finds dozens of annotationdriven clusterings with false discovery rate lower than 10% and size of the small subgroup larger than 5 on most of our evaluation studies, it does not find any clustering in four datasets. In Yeoh et al., 2002 very heterogeneous expression profiles caused by chromosomal aberrations are included, thus leading to a large number of significant annotation driven clusterings. We observe that our algorithm typically finds fewer annotation driven clusterings in small datasets, where the minimal group size criteria is more stringent.
The set of annotation driven clusterings for one project may be quite heterogeneous. Figure 2 illustrates such a case occurring in the study on embryonic brain tumours by Pomeroy et al., 2002. Stratifying these tumors by morphological features is controversial. Hence, they present an interesting field of research for diagnosis on a molecular level. The authors of this study acknowledge that the investigated tumours are very heterogeneous. In accordance with this observation, our method reports clearly differing annotation driven clusterings. Based on terms widely spread over the whole Gene Ontology, we determine 23 different gene sets justifying splits of samples into two groups on significantly better grounds than randomly picked genes.
Sorting out splits with little support
In Section 2.4, we describe in detail, how splits are evaluated. The DLD scores use to this end are computed on expression values from the most differential genes in a given split. In order to mask splits, which are supported by very few genes, we recommend to discard the n top-most differential genes from the determination of DLDscores. We consider such splits to be of little interest and prone to be artefacts. In order to demonstrate the efficiency of masking, we have analysed the dataset by Ross et al. (2004) for various settings of this parameter. Figure 3 illustrates our observations. Pomeroy et al. (2002) . Colors code the cluster to which a patient is attributed with respect to the corresponding gene set. In the gene set descriptions to the right of the image, the GO source ontologies of the annotations are indicated by BP (biological process), CC (cellular component) and MF (molecular function). Columns correspond to samples and rows to gene sets. The image is clustered in both directions in order to bring similar clusterings and sample profiles close together. The depicted set of clusterings achieves a false discovery rate of 8.8%.
We have computed DLD scores for each split of the dataset by ?, ignoring 0, 1 . . . 19 genes respectively. This yields 20 different rankings of splits. For the top most splits of each ranking, we have computed the number of differentially expressed genes among all genes associated to the corresponding annotation. In Figure 3 , the median of differential genes from the top ranked splits is related to the number of genes ignored when generating the ranking. We see that taking into account all genes in the evaluation of splits, places many splits with very few supporting genes at the top of the lists. Ignoring a moderate number of genes improves this behaviour and setting this parameter higher than 5 does no longer improve the wide support of top ranked splits.
Coherence between clusterings and phenotype
The cited datasets from clinical microarray studies come with clinical information. For instance, in the lung-cancer study discussed in Bhattacharjee et al., 2001 , histologically defined subtype assignments are provided for the biopsies, while in Ross et al., 2004 , cytogenetically determined translocations are given for each patient. In order to assess the clinical relevance of identified significant clusterings, we compare these with clinical parameters. We expect that our method rediscovers clinically relevant patient subgroups and characterizes them with related biological terms. The clinical parameters were not used in the unsupervised class finding procedure. In order to confirm this ability, we have applied χ 2 -tests to detect annotation-driven clusterings which are highly correlated with categorical clinical parameters.
On several datasets, we observed clusterings of striking correlation with clinical parameters, thus supporting previous findings. For instance, on the acute myeloid leukemia (AML) data set of Ross et al., 2004 , we found 11 patient splits for which the two groups correspond to some phenotypical separation of the samples. Less than 10 profiles are attributed inconsistently by these splits to the corresponding phenotypical separation and χ 2 contingency table tests yield p-values below 10 −10 . Seven of these clusterings consistently separate the group of megakaryocytic leukemia profiles plus one other profile described as having an unspecified AML subtype from the other AML subtypes. The 7 clusterings stem from gene sets annotated to blood coagulation (GO:0007596) and related GOterms. See Figure 4 for a display of the relationships between the 7 GO-terms and their ancestors within the Gene Ontology.
On the lung-cancer dataset by Bhattacharjee et al., 2001 , we identified 17 clusterings showing p-values < 10 −10 in the χ 2 -test and differing by not more than 10 cluster assignments from the corresponding morphological classification of the tumors. 9 of these clusterings separate the group of 20 pulmonary carcinoid tumors from all other tumors. Five of the 9 clusterings also assign one or two other profiles to the cluster of carcinoid tumors. The 9 clusterings are derived from gene sets annotated to central nervous system development (GO:0007417), ion channel activity (GO:0005216) and related terms.
DISCUSSION
An important goal of clinical microarray studies is the discovery of cohesive subgroups of patients according to molecular criteria. Commonly, unsupervised clustering is employed to this aim, although the evaluation of clustering results is notoriously difficult. One suggestion, to show whether a clustering is biologically meaningful, is to point out that functional annotation of the genes supporting the clustering are coherent or plausible.
In this paper, we propose an algorithm to use functional annotations stored in the Gene Ontology and the KEGG database of pathways directly to search for cohesive groups of samples. By selecting genes sharing common annotation in GO or KEGG and limiting gene expression profiles to these, we define distinct distances between samples for each term or pathway. Consequently, different clusterings are found for each GO term or KEGG pathway. A notable difference to other approaches to select genes before clustering (e.g., Bullinger et al., 2004) is that the selection stems from independent data, which represent biological expert knowledge and are not affected by experimental variations.
The use of GO and KEGG to extract functional annotations leads to the inclusion of some unreliable data. These databases are always incomplete and their computationally derived annotations may contain errors. However, we expect our approach to be robust against such erroneous annotation data, since clusterings are always supported by several genes with common annotation. Currently our method is limited to clusterings into two groups. This is mainly done to ensure comparability of clustering scores and to allow for a meaningful statistical analysis. However, our method can easily be applied iteratively taking only the samples in one of the clusters, to see whether a different biological theme could help to divide this one cluster into sub-clusters. Since the iterations of this clustering procedure can rely on different gene sets, the procedure is even more flexible than allowing for more than two clusters in the original algorithm.
In our evaluation on cancer related data sets (see Table 1 ) we found several significant annotation driven clusterings, which strongly correlate with clinical patient stratifications. Moreover, the driving genes often confirm previous reports on the biology behind tumor development. For instance, for the acute myeloid leukemia (AML) data set of Ross et al., 2004 , we found a large number of significant clusterings. AML is a heterogeneous disease, comprising abnormal proliferation of the precursors of granulocytes, monocytes, and thrombocytes (Jaffe et al., 2001) . Thus, it is not surprising to find many significant clusterings separating one type of AML from the rest. For example, 7 clusterings that separate AML of the FAB-M7 type, i.e. acute megakaryocytic leukemia, from the other AML types, are based on gene sets attributed to blood coagulation, cell adhesion and five related terms. Since megakaryocytes give rise to thrombocytes, whose primary function is to mediate cell adhesion to damaged endothelium and blood coagulation, they are bound to excel in the expression of genes involved in these processes. Remarkably, one patient profile that was clinically described as having an unspecified AML subtype is consistently assigned to the cluster of FAB-M7 samples. This sample seems to display molecular characteristics of the FAB-M7 subtype, although it would not be assigned to this subtype based on clinical criteria.
In accordance with other studies, Bhattacharjee et al., 2001 have described lung cancer to be a general concept comprising very different tumor subtypes. We as well observe large biological differences between these subtypes in form of significant annotation driven clusterings. For example, 9 clusterings clearly separate pulmonary carcinoid tumors from all other types of lung cancer. These 9 clusterings are derived from gene sets annotated to central nervous system development (GO:0007417), ion channel activity (GO:0005216) and 7 related terms. Pulmonary carcinoid tumors have been previously reported to be of neuroendocrine origin and to be closely related to brain tumors (Anbazhagan et al., 1999) . Our finding of remarkable expression of nerve-cell associated genes by these tumors supports such reports.
In summary, the method presented in this paper has the potential to uncover clinically relevant clusterings in gene expression studies. Moreover, such clusterings may be of particular interest due to the biological focus of their supporting genes.
